Clinical Trial

A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB). Researchers want to learn about MK-4646 when taken at the same time as Rifabutin. They want to: Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-22; most recent amendment 2026-01-27.
Status change: Active, Not Recruiting → Completed 2026-01-27
Status change: Recruiting → Active, Not Recruiting 2025-11-21
Status change: Not Yet Recruiting → Recruiting 2025-10-31
Trial Details
NCT Number NCT07199452
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 18 participants
Start Date 2025-10-28
Primary Completion 2025-12-27 (estimated)
Study Completion 2026-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-29